Patient P-01726
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
27%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
- Day 17 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 17.
Primary contributors, last 14 days
- GI instability+14
- Inflammatory activity+7
- Toxicity-5
- Treatment adherence-3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion15.7/100
worsening · +3.5 vs previous 14 d
Toxicity
Blood14.3/100
stable · +0.3 vs previous 14 d
Sleep quality
Wearable56.9/100
stable · +0.9 vs previous 14 d
Energy level
Daily log6.7/10
improving · +0.4 vs previous 14 d
Stress level
Daily log3.4/10
worsening · +0.2 vs previous 14 d
Steps
Wearable3,363
stable · -44 vs previous 14 d
Adherence
Companion92.4 %
stable · +2.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 91 from the failing basin, 10 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+1no signal · 26%
- Alcohol-0.4no signal · 15%
- Insoluble fibre+0.3no signal · 15%
- Spicy / capsaicin-0.3no signal · 15%
- Dietary fat load-0.1no signal · 15%
- Simple carbohydrates-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↓20
- Wearable3,363 steps/day
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.7 · butyrate capacity 59/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 42 ms
- Sleep
- 7.0 h
- Steps
- 3,009
- Resting HR
- 57 bpm
Daily log: GI score 16, nutritional resilience 72, adherence 92.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.